A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)

I4V-MC-KHAA -

The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
COVID-19
What the trial is testing?
Baricitinib
Could I receive a Placebo?
Yes
Enrollment Goal
1525
Trial Dates
Jun 12, 2020 - Jun 10, 2021
How long will I be in the trial?
The study will last about 6 weeks and may include up to 7 visits as well as daily assessments.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Be hospitalized with coronavirus (SARS-COV-2)

  • Need oxygen therapy when they enter the study and when assigned to treatment

Participants Must Not:

  • Have ever received convalescent plasma or intravenous immunoglobulin [IVIg]) for COVID-19

  • Have received greater than 20 milligrams per day of oral corticosteroids for more than 14 days before study start

  • Have received antibodies that block the COVID-19 virus

  • Have active tuberculosis (TB)

  • Have an active infection (besides COVID-19)

  • Require a ventilator at study entry

  • Have cancer

  • Have a history of more than one blood clot or a blood clot within 12 weeks before entering study

  • Be pregnant or breastfeeding

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.